Photo: Tim Robberts/Getty Images
Assort Health, which offers an agentic AI patient experience platform, announced it has closed a $76 million Series B funding round led by Lightspeed Venture Partners, bringing its total raise to $102 million.
First Round Capital, Felicis, Chemistry, A*, Liquid2 and Quiet Capital participated in the round.
Galym Imanbayev, partner at Lightspeed Venture Partners, will join the company's board of directors, and Paul Ricci, founding CEO of Nuance, will join the board as an advisor.
WHAT IT DOES
The company's platform, Assort OS, delivers specialty-specific agentic AI agents that answer calls across voice, text and web, including calls pertaining to appointment scheduling, care navigation, prescription renewals, physician referrals and lab tests.
The California-based company will use the funds to expand its workforce and speed up the development of its Assort OS platform.
"We are thrilled to back Assort Health as it leads the re-platforming of patient engagement into the AI-native era with superior experience for patients and unprecedented outcomes for the organizations that care for them," Imanbayev of Lightspeed Venture Partners said in a statement.
MARKET SNAPSHOT
In April, Assort Health secured $22 million in Series A funding, led by First Round Capital and Chemistry, with participation from Quiet Capital. The funding brought the company's total raise to $26 million.
The company scored $3.5 million in seed funding in 2024.
Another company offering AI to assist with patient calls is Providertech – its voice-first conversational AI answers incoming calls, helps with scheduling and updating appointments, and responds to commonly asked questions.
